A buzzwordy biotech comes (mostly) out of stealth
Cellarity, a startup from Flagship Pioneering blending the buzzy fields of single-cell sequencing and artificial intelligence, officially launched this morning.
STAT first reported details of the new company's plans in December, as well as its new name in May. Cristina Rondinone, formerly of AstraZeneca's MedImmune subsidiary, is the company's president; the company's chief technology officer is Chad Nusbaum, who joined after nearly 20 years at the Broad Institute.
Instead of working on a specific pathway or target, Cellarity's CEO Avak Kahvejian told STAT the company will be looking at how something affects a cell's "behavior." According to the company's press release, its scientists have identified "a large number of lead candidates" in the past year.
Cellarity's leadership isn't disclosing how much money the company has, though Kahvejian (who is also a Flagship partner) told STAT the company had closed a series A.
STAT first reported details of the new company's plans in December, as well as its new name in May. Cristina Rondinone, formerly of AstraZeneca's MedImmune subsidiary, is the company's president; the company's chief technology officer is Chad Nusbaum, who joined after nearly 20 years at the Broad Institute.
Instead of working on a specific pathway or target, Cellarity's CEO Avak Kahvejian told STAT the company will be looking at how something affects a cell's "behavior." According to the company's press release, its scientists have identified "a large number of lead candidates" in the past year.
Cellarity's leadership isn't disclosing how much money the company has, though Kahvejian (who is also a Flagship partner) told STAT the company had closed a series A.
No hay comentarios:
Publicar un comentario